Acylated- and unacylated ghrelin during an oral glucose tolerance test in humans at risk for type 2 diabetes mellitus.

Magnus WolfMartin HeniAnita M HennigeKatrin SippelAlexander CeganLina María Serna HiguitaPeter MartusHans-Ulrich HäringAndreas FritscheAndreas Peter

Published in: International journal of obesity (2005) (2023)

Our data demonstrate lower concentrations for both AcG and UnG with increasing BMI as well as an increased proportion of the biologically active, acylated form of ghrelin giving point to pharmacologic intervention in ghrelin acylation and/or increase in UnG for treatment of obesity despite decreased absolute AcG levels.

Keyphrases

randomized controlled trial
weight gain
metabolic syndrome
type diabetes
insulin resistance
body mass index
weight loss
growth hormone
electronic health record
big data
adipose tissue